Patent ID: 8563507

Claim:
A method of treating a disease or condition characterized by aberrant epithelial cell proliferation and/or migration, said method including the step of administering to a mammal an agent which disrupts an isolated protein complex comprising: insulin-like growth factor I (IGF-I); an insulin-like growth factor binding protein (IGFBP) selected from IGFBP-3 and IGFBP-5; and vitronectin; or which prevents formation of the isolated protein complex, to thereby treat said disease or condition in said mammal, wherein the agent is selected from the group consisting of IGF-II and IGF-II having a deletion or non-conservative substitution of one or more amino acid residues selected from: (i) V35; (ii) S36; and (iii) S39; of an RVSRRSR (SEQ ID NO:1) sequence at positions 34-40 in the C-domain of IGF-II.